Trial · NCT02807857
Results by group229
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 229
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Enrolled Set | Level 1: Drug Type : Adherent | 110 | Participants | |
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Follow-Up Set | Level 1: Drug Type : Adherent | 59 | Participants | |
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Enrolled Set | Level 1: Drug type : Not Adherent | 802 | Participants | |
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Follow-Up Set | Level 1: Drug type : Not Adherent | 523 | Participants | |
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Enrolled Set | Patients missing LVEF values | 503 | Participants | |
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist) | Follow-Up Set | Patients missing LVEF values | 279 | Participants | |
| Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose | Follow-Up Set | Adherence at V2, not adherent at V1 for drug type | 3.3 | Percentage of Patients | |
| Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose | Follow-Up Set | Adherence at V2, not adherent at V1:drug type/dose | 0.8 | Percentage of Patients | |
| Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose | Follow-Up Set | Adherence at V2 and V1 for drug type | 79.2 | Percentage of Patients | |
| Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose | Follow-Up Set | Adherence at Visit 1 for drug type & dose | 86.7 | Percentage of Patients | |
| Duration of Heart Failure | Enrolled Patients | >3 years | 896 | Participants | |
| Duration of Heart Failure | Follow-Up Set | >3 years | 549 | Participants | |
| Duration of Heart Failure | Enrolled Patients | ≤3 years | 517 | Participants | |
| Duration of Heart Failure | Follow-Up Set | ≤3 years | 312 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Enrolled Set | Diuretics - without mineral corticoid antagonists | 934 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Follow-Up Set | Diuretics - without mineral corticoid antagonists | 625 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Enrolled Set | Beta blocking agents | 981 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Follow-Up Set | Beta blocking agents | 602 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Enrolled Set | Agents acting on the renin-angiotensin system | 834 | Participants | |
| Number of Patients With Current Use of Concomitant Compound | Follow-Up Set | Agents acting on the renin-angiotensin system | 491 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02807857/results